Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Varsha Gandhi, PhD, on Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Feb

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Varsha Gandhi, PhD, on Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer

MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer

Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy

Adjuvant Coformulated Vibostolimab Plus Pembrolizumab in High-Risk Stage IIB to IV Melanoma

Microplastics Found in 90 Percent of Prostate Cancer Samples